CureVac raises equity to fund Covid-19 vaccine rollout

CureVac_2_575_375
By Aidan Gregory
26 Jan 2021

CureVac, the German biotechnology company, has launched a $523m share sale to fund late stage clinical trials for its Covid-19 vaccine, and an expansion of its manufacturing capacity.

Launched after the market close in New York on Monday evening, the sale of new stock is CureVac’s first follow-on offering since its $213m IPO on the Nasdaq in August.

Since the flotation, shares in CureVac have surged by over 550%, giving the company a market ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial

Want to learn more? View subscription options